Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Humacyte, Inc. Director's Dealing 2023

May 26, 2023

33410_dirs_2023-05-26_ce7d8e6c-c6f2-496f-b3d4-24496964d797.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2023-05-24

Reporting Person: Prichard Heather Ledbetter (Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-24 Common Stock M 13789 $1.19 Acquired 22978 Direct
2023-05-24 Common Stock S 13789 $4.14 Disposed 9189 Direct
2023-05-25 Common Stock M 64990 $1.19 Acquired 74179 Direct
2023-05-25 Common Stock S 9613 $3.83 Disposed 64566 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-05-24 Stock Options (right to buy) $1.19 M 13789 Disposed 2023-11-22 Common Stock (13789) Direct
2023-05-25 Stock Options (right to buy) $1.19 M 64990 Disposed 2023-11-22 Common Stock (64990) Direct

Footnotes

F1: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.14 to $4.16. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.82 to $3.89. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.